Pharmacological properties Mometasone Furoate
Pharmacodynamics
Mometasone Furoate – is a synthetic glucocorticosteroid (GCS), anti-inflammatory effect. Like other topical corticosteroids, mometasone furoate has antipruritic, and vasoconstrictive antiexudative action. In general, the mechanism of anti-inflammatory topical corticosteroids is unclear. Suggest that corticosteroids induce the release of proteins that inhibit phospholipase A2, and collectively known as lipokortiny. These proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes, by inhibiting the release of their common predecessor – arachidonic acid.
Pharmacokinetics
The degree of penetration of Mometasone Furoate through the skin depends on various factors, including the composition of the preparation and integrity of the epidermal barrier. Studies in humans have shown that approximately 0.4% applied on intact skin dose (without occlusive dressings) 0.1% cream Mometasone Furoate was detected in the circulation after 8 hours, inflammatory and other processes occurring in the skin may cause to enhance the penetration of drugs through the skin.
Mometasone Furoate Indications for Use
Inflammations and itching in Medicine, treatable glucocorticosteroids (GCS), the state, accompanied by hyperkeratosis (atopic and seborrheic dermatitis, psoriasis, chronic eczema) in adults and children aged two years.
Dosing and Administration Mometasone Furoate
Medication Mometasone Furoate Cream for external use only 0,1% is intended for cutaneous applications in dermatology and is not intended for use in ophthalmology.
A thin layer of cream with Mometasone Furoate is applied to affected skin once a day. Dosage form of Mometasone Furoate, the scheme and the duration of treatment should identify the doctor.
Side effects Mometasone Furoate
When skin application of the drug is very rarely can occur following local reactions: burning, itching, skin atrophy, the appearance of pink acne.
When the local use of various corticosteroids can rarely occur following adverse events – in descending order of frequency of occurrence – irritation and dryness, folliculitis, hypertrichosis, ugrevidnaya rash, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, striae and miliaria. The likelihood of these adverse events increases with the use of occlusive dressings.
Contraindications Mometasone Furoate
The drug is contraindicated in patients with symptoms of hypersensitivity to any component of it.
Overdose Mometasone Furoate
Systemic absorption when applied topically with a cream Mometasone Furoate may cause systemic effects. Treatment is symptomatic.
Features of Mometasone Furoate
Should not enter the drug in the eye.
As a result of systemic absorption when applied topically different corticosteroids may be reversible suppression of hypothalamic-pituitary-adrenal system, as well as the symptoms of glucocorticosteroid insufficiency after withdrawal of the drug. Patients as a result of systemic absorption of corticosteroids when applied topically can also develop Cushing’s syndrome, hyperglycemia and glucosuria.
Patients receiving topical corticosteroids for the treatment of large areas of skin, or with occlusive dressings should be inspected periodically for signs of suppressing the function of the hypothalamic-pituitary-adrenal axis. Such a test can be performed through a test with ACTH-stimulation, measurements of morning cortisol in plasma and in other media, except for urine. In the event that marked inhibition of this system should increase the interval between coats or the use of less active GCS, or cancel the product. Restoring the function of the hypothalamic-pituitary-adrenal system generally occurs shortly after the abolition of the local SCS. Sometimes it may appear the signs and symptoms of glucocorticosteroid insufficiency, which requires the additional use of systemic corticosteroids. If it is not prescribed by a doctor, the drug should not be applied to the face, as well as in the axillary and inguinal folds.
If irritation occurs, discontinue use of Mometasone Furoate, and appropriate treatment. Allergic contact dermatitis in the application of corticosteroids is usually diagnosed on the basis of treatment failure, rather than on clinical symptoms of exacerbation, as is done in the local application of drugs that do not contain corticosteroids. Such surveillance should be reinforced through applicative skin test.
In the case of concomitant infections of the skin to apply an appropriate antifungal or antibacterial agent. If, within a short time can not reach the positive dynamics, the application of Mometasone Furoate cream should be suspended until such time until the infection is completely eliminated.
If within 2 weeks after initiation of therapy no improvement is necessary to clarify the diagnosis.
Application in pediatrics Mometasone Furoate
Children under the age of 2 years, only drug used only on prescription.
Due to the fact that in children the value of the ratio of surface area and body weight than adults, children are at greater risk of oppression of the function of the hypothalamic-pituitary-adrenal system and the emergence of Cushing’s syndrome in the application of any topical corticosteroids, which rises when applied to the GCS area of more than 20% of body surface. For the same reason, the risk of adrenal insufficiency when canceling topical corticosteroids treatment in children above. In the treatment of local corticosteroids in children is easier to appear atrophic skin changes until the appearance of stretch marks.
Mometasone Furoate should not be used for the treatment of dermatitis caused by wearing diapers.
The cream should not be used under occlusive dressings unless directed by your doctor, also applied to the areas covered by diapers or waterproof shorts, since in this case, the cream will be under the occlusive bandage.
Use during pregnancy or breastfeeding. Mometasone Furoate cream used during pregnancy only if the expected benefits to the mother exceeds potential risk to the fetus.
Lactating women should stop breastfeeding for a period of treatment with Mometasone Furoate.
Impact on driving ability, and other mechanical means. Data on the adverse effects of the drug’s ability to operate vehicles and machinery available.
Interaction with other drugs
Interactions with other drugs to date have not been described. Chemical properties Mometasone Furoate is not compatible with alkalis.
